Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
Qian Dong(Liaoning Cancer Hospital & Institute), Xiujuan Qu(First Hospital of China Medical University), Yao Zhang(Central South University), Xianghong Yang(China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Wei Jing(Lanzhou University), Liqiang Zheng(Shanghai Jiao Tong University)
Cited by 69
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
|New England Journal of Medicine|2020|432